Xcout Intel
Actio Biosciences
Actio Biosciences is a privately held biotechnology company utilizing genomic medicine to discover and develop treatments for rare diseases and epilepsy.
Subscribe to see Actio Biosciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Actio Biosciences at a glance
Actio Biosciences is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $66M in June 2025. Xcout tracks 16 named people at Actio Biosciences, including Sunil Sahdeo (Chief Operating Officer).
Actio Biosciences leadership
- Sunil SahdeoChief Operating Officer
- Cayce DentonChief Financial Officer
- David BreckenridgeChief Scientific Officer
- Pete CondonChief Business Officer
- David GoldsteinCEO, Co-founder
- John McHutchisonCo-founder
10 more named people on record for Actio Biosciences, with roles, board committees and tenure — see the full roster →
Actio Biosciences funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $66M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Actio Biosciences news
- AcquisitionJazz Pharmaceuticals Completes Acquisition of Actio Biosciences
- AcquisitionJazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
- AcquisitionJazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio - CNBC
- AcquisitionJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio - PR Newswire
Investors
Actio Biosciences competitors
A few of Actio Biosciences's closest competitors — see the full list of competitors and alternatives →
Addition Therapeutics is a biotechnology research company based in South San Francisco, California. The firm is on a mission to fulfill the promise of genomic medicine for chronic and rare diseases, having emerged from stealth with significant funding.
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Vico Therapeutics is a neurology genetic medicine and biotechnology company pioneering targeted treatments for devastating disorders from its location at the BioScience Park.
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.
Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.
Get Actio Biosciences's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Actio Biosciences in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access